On June 27, 2024, Hualing Pharmaceuticals announced that, according to the amended Securities Listing Rules of the Hong Kong Stock Exchange, the company will adopt electronic means to publish its corporate communications starting from December 31, 2023. In the future, corporate communications will no longer be mailed in print form to non-registered shareholders, unless individual shareholders request it. The Chinese and English versions of corporate communications will be available on the websites of Hualing Pharmaceuticals and the Hong Kong Stock Exchange. If shareholders provide a valid email or mailing address, the company will send a notification of the release of the website version of the communications. Shareholders who wish to continue receiving print copies need to fill out an application form and submit it before December 31, 2024. In addition, shareholders can contact the share registry office by phone or email at any time to inquire.

On June 27, 2024, Hualing Pharmaceuticals announced that, according to the amended Securities Listing Rules of the Hong Kong Stock Exchange, the company will adopt electronic means to publish its corporate communications starting from December 31, 2023. In the future, corporate communications will no longer be mailed in print form to non-registered shareholders, unless individual shareholders request it. The Chinese and English versions of corporate communications will be available on the websites of Hualing Pharmaceuticals and the Hong Kong Stock Exchange. If shareholders provide a valid email or mailing address, the company will send a notification of the release of the website version of the communications. Shareholders who wish to continue receiving print copies need to fill out an application form and submit it before December 31, 2024. In addition, shareholders can contact the share registry office by phone or email at any time to inquire.